Related Experiment Videos
[The effect of pefloxacin on nephrotic syndrome in experimental adriamycin nephropathy]
Background:
Antiproteinuric effect of pefloxacine was demonstrated in a small group of patients with minimal change nephropathy (MCN) and focal and segmental glomerulosclerosis (FSGS). This finding was not, however, confirmed by other papers. Adriamycine nephropathy is an experimental model of nephrotic syndrome with morphological changes resembling MCN and/or FSGS in patients.
Methods And Results:
Nephrotic syndrome was induced in rats by the i.v. administration of adriamycine. One part of nephrotic animals was treated from the beginning of the 4th week by daily intraperitoneal application of pefloxacine. Administration of adriamycine led in experimental animals after 3 weeks to the development of full-blown nephrotic syndrome with further progression of proteinuria in the next 3 weeks (from 1.4 +/- 1.25 to 2.23 +/- 1.89 g of protein/mmol of urinary creatinine, p < 0.05). Proteinuria did not change in nephrotic rats treated by pefloxacine (from 1.04 +/- 0.97 to 1.26 +/- 1.11 g of protein/mmol of urinary creatinine, p = n.s.). The difference in proteinuria between both groups was also significant (0.83 +/- 0.73 vs. 0.23 +/- 0.67 g of protein/mmol of urinary creatinine, p < 0.05).
Conclusions:
Pefloxacine was antiproteinuric in experimental adriamycine nephropathy. The mechanism of this effect remains unclear and deserves further studies concentrating on glomerular cytokine network and glomerular production of reactive oxygen species.
Insights
Pefloxacine demonstrated an antiproteinuric effect in experimental adriamycine nephropathy, reducing protein loss in urine. Further research is needed to understand the exact mechanism behind this beneficial effect in nephrotic syndrome models.
Area of Science:
- Nephrology
- Pharmacology
Context:
- Minimal change nephropathy (MCN) and focal segmental glomerulosclerosis (FSGS) are kidney diseases characterized by proteinuria.
- Adriamycine nephropathy serves as an experimental model for nephrotic syndrome, mimicking human MCN and FSGS.
Purpose:
- To investigate the antiproteinuric effect of pefloxacin in an experimental model of nephrotic syndrome induced by adriamycine.
- To evaluate the efficacy of pefloxacin in reducing proteinuria in adriamycine-induced nephropathy in rats.
Summary:
- Adriamycine administration induced nephrotic syndrome and progressive proteinuria in rats.
- Daily intraperitoneal pefloxacin treatment significantly reduced proteinuria in nephrotic rats compared to untreated controls.
- Pefloxacin administration prevented the increase in proteinuria observed in the progression phase of adriamycine nephropathy.
Impact:
- Pefloxacin exhibits an antiproteinuric effect in the adriamycine-induced nephropathy model.
- The findings suggest a potential therapeutic role for pefloxacin in managing proteinuria in specific nephrotic conditions.
- Further studies are warranted to elucidate the underlying mechanisms, focusing on glomerular cytokines and reactive oxygen species.